Compile Data Set for Download or QSAR
Report error Found 160 Enz. Inhib. hit(s) with all data for entry = 11301
TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510974(5-methyl-1-[4-(1-methyl- 1H-pyrazol-4-yl)phenyl]- ...)
Affinity DataIC50: 0.800nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510980(1-(2,2-difluoroethyl)-6-(2- hydroxy-2- methylpropo...)
Affinity DataIC50: 1.10nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510981(1-(2,2-difluoroethyl)-6-(2- fluoro-2-methylpropoxy...)
Affinity DataIC50: 1.60nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510905(6-(2-hydroxy-2- methylpropoxy)-N- [(aR)-6-({6- car...)
Affinity DataIC50: 2.20nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510975(1-(difluoromethyl)-5-(4- methanesulfonylphenyl)- N...)
Affinity DataIC50: 2.30nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510976(5-(4-cyanophenyl)-1- (difluoromethyl)-N-[(4s)- 6-(...)
Affinity DataIC50: 2.70nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510968(7-cyclopropyl-6-(2- hydroxy-2- methylpropoxy)-N-[(...)
Affinity DataIC50: 2.90nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510977(5-(3- methanesulfonylphenyl)- N-[(4s)-6-({5-carbam...)
Affinity DataIC50: 4.30nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM605590(US11673886, Example 69 | 1-cyclopropyl-3- ({(aR)-6...)
Affinity DataIC50: 4.5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510979(1-{4-[1-(2,2- difluoroethyl)-1H-pyrazol- 4-yl]phen...)
Affinity DataIC50: 4.60nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510830(US11078197, Example 7 | US11673886, Example 7)
Affinity DataIC50: 4.80nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510924(6-fluoro-N-[(aR)-6- ({5-carbamoyl-1- methyl-1H- py...)
Affinity DataIC50: 5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510967(US11078197, Example 146 | US11673886, Example 146)
Affinity DataIC50: 5.20nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510882(1-cyclopropyl-3- {[(aR)-6-[6-(6- fluoropyridin-3-y...)
Affinity DataIC50: 5.30nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510831(US11078197, Example 8 | US11673886, Example 8)
Affinity DataIC50: 5.40nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510922(1-methyl-6-{[(aR)- 6-[6-(2-hydroxy-2- methylpropox...)
Affinity DataIC50: 6nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510886(2-cyclopropyl-4- {[(aR)-6-[6-(6- fluoropyridin-3-y...)
Affinity DataIC50: 6.10nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510973(1-(4-cyanophenyl)-5- methyl-N-[(4s)-6-({5- carbamo...)
Affinity DataIC50: 6.30nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510848(N-{(aR)-6-[(5- carbamoyl-2- methyl-1,3-thiazol-4- ...)
Affinity DataIC50: 6.40nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510843(3-({(aR)-6-[7- cyclopropyl-6-(2- hydroxy-2- methyl...)
Affinity DataIC50: 6.80nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510897(5-({6-[6-( 2- hydroxy-2- methylpropoxy) pyrazolo[1...)
Affinity DataIC50: 6.80nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510845(4-({(aR)-6-[7- cyclopropyl-6-(2- hydroxy-2- methyl...)
Affinity DataIC50: 7nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510971(1-(4- methanesulfonylphenyl)-5- methyl-N-[(4s)-6-(...)
Affinity DataIC50: 7.10nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510853(3-({(aR)-6-[7- cyclopropyl-6-(2- hydroxy-2- methyl...)
Affinity DataIC50: 7.70nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510923(1-methyl-6-{[(aR)-6-(3- cyanobenzamido) spiro[3.3]...)
Affinity DataIC50: 8nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510894(2-(((aR)6-(7- cyclopropyl-6-(2- hydroxy-2- methylp...)
Affinity DataIC50: 8.70nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510904(5-{[(aR)-6-(3- cyanobenzamido) spiro[3.3]heptan-2-...)
Affinity DataIC50: 9.70nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM605538(US11673886, Example 19 | 3-({(aR)-6-[7- cyclopropy...)
Affinity DataIC50: 10.5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510978(1-methyl-6-{[(4s)-6-[1- (2,2-difluoroethyl)-1H- py...)
Affinity DataIC50: 10.9nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510887(2-cyclopropyl-4- {[(aR)-6-[3- (trifluoromethyl) im...)
Affinity DataIC50: 11.4nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM605583(US11673886, Example 62 | 2-cyclopropyl-4- {[(aR)-6...)
Affinity DataIC50: 11.6nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510918(3-methyl-5-{[(aR)- 6-[6-(2-hydroxy-2- methylpropox...)
Affinity DataIC50: 12nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510931(US11078197, Example 110 | 2-cyclopropyl-4- {[{aR)-...)
Affinity DataIC50: 12.2nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510838(3-({(aR)-6-[7- cyclopropyl-6-(2- hydroxy-2-methylp...)
Affinity DataIC50: 12.5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510841(4-({(aR)-6-[7- cyclopropyl-6-(2- hydroxy-2- methyl...)
Affinity DataIC50: 13.4nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510972(5-(2,4-difluorophenyl)-N- [(4s)-6-({5-carbamoyl-1-...)
Affinity DataIC50: 13.6nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510865(1-(difluoromethyl)- 6-(2-hydroxy-2- methylpropoxy)...)
Affinity DataIC50: 13.7nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510850(1-(3-aminopropyl)- 3-({(aR)-6-[7- cyclopropyl-6-(2...)
Affinity DataIC50: 13.8nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510837(3-({(aR)-6-[7- cyclopropyl-6-(2- hydroxy-2- methyl...)
Affinity DataIC50: 14.1nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510970(N-[(4s)-6-({5-carbamoyl- 1-methyl-1H-pyrazolo[3,4-...)
Affinity DataIC50: 14.5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510880(1-cyclopropyl-3- {[(aR)-6-[6-(2,2- difluoroethoxy)...)
Affinity DataIC50: 15.9nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510857(4-[((aR)-6-{6-[3- (chloromethyl)-3- (hydroxymethyl...)
Affinity DataIC50: 17.2nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510942(1-(difluoromethyl)-6-(2- hydroxy-2- methylpropoxy)...)
Affinity DataIC50: 18.3nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510840(4-({(aR)-6-[6-(2- hydroxy-2- methylpropoxy)pyrazol...)
Affinity DataIC50: 18.5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510844(4-({(aR)-6-[6-(2- hydroxy-2- methylpropoxy)pyrazol...)
Affinity DataIC50: 18.9nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM605521(US11673886, Example 2)
Affinity DataIC50: 20nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510903(N-[6-({3-carbamoyl- 5H,7H,8H- pyrano[4,3- b]pyridi...)
Affinity DataIC50: 20nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510827(US11078197, Example 4 | US11673886, Example 4)
Affinity DataIC50: 20.1nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510954(1-(difluoromethyl)-6-(2- hydroxy-2- methylpropoxy)...)
Affinity DataIC50: 20.2nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM510876(1-(difluoromethyl)- 3-{[(aR)-6-[6- (2,2,2-trifluor...)
Affinity DataIC50: 22nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 160 total ) | Next | Last >>
Jump to: